Finance

There are likely much better routes to take for the average investor.

A gloomy update from a famous peer negatively affected investor sentiment on CRM company.

Several top-level government security agencies issued a fresh warning about cyber threats.

Robinhood’s entry into crypto means there’s a new top dog to beat.

AI stocks have slipped in recent weeks.

This was partially due to a broad investor pivot away from software companies into hardware makers.

Microsoft’s sell-off doesn’t make a lot of sense.

Inflation cooled faster than expected in June, but Fed Chair Kevin Warsh isn’t ready to declare victory.

The leading AI labs face a severe compute shortage, and custom silicon could help solve it.

Rushing into that stage of life could come back to bite you.

On July 14, 2026, cooling consumer prices sparked a broad tech rebound.

The nuclear technology company surged in 2025 but has tumbled in the first half of 2026.

Can Ur-Energy earn money selling uranium? One analyst thinks so.

Years of progress are hard to see without any commercial results yet.

Do yourself a favor and do not follow my lead.

It’s a factor you may not be able to control.

You don’t want to put your hard-earned savings at risk.

Last month, the U.S. Department of Health and Human Services (HHS) announced Operation Trailblazer, including a coordinated package of reforms to the U.S. Food and Drug Administration’s (FDA’s) Investigational New Drug (IND) application process, intended to reduce the time and cost required to initiate first-in-human clinical trials. The announcement comes amid significant erosion in the US’ share of early-stage pharmaceutical development, thanks largely to deregulation in China over the past few years. According to HHS, its reforms could reduce early stage development timelines by 6 to 12 months.

SK Hynix stock had its worst day ever in its home market.